Clinical Validation of the Lexie Lumen Over the Counter Hearing Aid
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hearing Loss
- Sponsor
- hearX Group
- Enrollment
- 68
- Locations
- 1
- Primary Endpoint
- Abbreviated Profile of Hearing Aid Benefit (APHAB)
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
More than half a billion people globally have hearing loss. Most hearing loss is sensorineural, meaning that the hearing loss is irreversible and requires rehabilitation. The majority of people with hearing loss have mild to moderate degrees, for which the most effective treatment options are hearing aids. Over the past few years, there have been many developments in hearing technology and the service delivery models in which they are supplied. Traditional hearing care models include several visits to a qualified hearing professional who must both perform diagnostics and prescribe hearing aids, which in the past has been the only way to obtain hearing aids. However, newer developments include forms of self-fitting hearing aids that enable a user to perform threshold measurements to determine the degree of hearing loss and automatically program and fine-tune hearing aids. These devices are now becoming available as direct-to-consumer (DTC) or over-the-counter (OTC) hearing aids. Furthermore, alternative care models have been suggested to bolster access and uptake of assistive technology for hearing loss. Regulations on DTC and OTC hearing aids are starting to come into effect. In 2017, the FDA Reauthorization Act of 2016 directed the FDA to create a category for OTC hearing aids for adults with perceived mild-to-moderate hearing loss. In October 2021, the FDA formally proposed a rule to establish the OTC hearing aid category as part of this process. These changes in regulations would mean that soon, many of these self-fitting devices will become available. In response to these changes in service delivery models, the hearX group recently developed the Lexie Lumen hearing aids that can perform in-situ hearing threshold estimations and automatically prescribe hearing aid gain settings that closely approximate the gold-standard NAL-NL2 fitting prescription. This study aims to evaluate whether the performance of the novel Lexie self-test and self-fitting hearing aid is equivalent to the same hearing aid programmed professionally by an audiologist using a professionally obtained audiogram.
Detailed Description
Objective: To examine the difference in outcomes (satisfaction and objective benefit) of the Lexie self-test and self-fitting (Lexie- STF) hearing aid versus a Lexie hearing aid fitted professionally with a clinically obtained audiogram (Lexie-PTF) (n = 60). Hypothesis: It is hypothesized that the Lexie-STF (experimental group) will be non-inferior to the Lexie-PFT (control group) in terms of perceived satisfaction, speech perception in noise and real-ear measurements. Design: A randomized control trial (RCT) will be conducted cross-sectionally (45 days) to evaluate the efficacy of Lexie-STF compared to Lexie-PTF. Setting: This study will involve clinical, audiometric testing as well as a user field-trial of the fitted hearing aids. Participants: Eligible participants will include 60 adults (18 to 99 years) with a self-perceived level of hearing loss, free from symptoms of ear disease or excessive cerumen and who own a smartphone (Android or iOS). Participants will be recruited for each group and will randomly be assigned using a computer-generated randomization by an independent research assistant, after being stratified for sex and degree of hearing loss. Intervention: The experimental group (Lexie-STF) will be provided with Lexie Lumen hearing aids and accompanying smartphone application, that will be automatically fitted according to the participants in-situ audiogram. Participants will then be able to self-adjust their hearing aid settings (prescriptive gain) after a period of two weeks. The control group (Lexie PTF) will be professionally fitted by a certified audiologist with the Lexie Lumen hearing aids, according to gold-standard NAL-NL2 prescriptive gain targets using a standard clinically obtained audiogram. Outcome measures: The main outcome measure is the Abbreviated Profile of Hearing Aid Benefit (APHAB). Secondary outcome measures will be the International Outcome Inventory for Hearing Aids (IOI-HA), the QuickSIN speech-in-noise test and real-ear-measurements (REMs).
Investigators
De Wet Swanepoel
Principal Investigator
hearX Group
Eligibility Criteria
Inclusion Criteria
- •Adults aged between the ages of 18 to 99 years, living in South Africa.
- •Good English proficiency (measured using an online English proficiency test as well as self-report of English speaking competence)
- •Must have a self-perceived hearing loss
- •Mild to severe sensorineural hearing loss (thresholds \<= 80 dB HL across frequencies bilaterally)
- •Possession of a smartphone compatible with the Lexie app (iOS or Android)
- •Access to mobile data to operate the Lexie app.
- •Willingness and availability to participate in the study over a period of 45 days
Exclusion Criteria
- •Normal hearing or profound hearing loss
- •Active outer or middle ear disease
- •Poor English proficiency
- •Diagnosed cognitive impairment
Outcomes
Primary Outcomes
Abbreviated Profile of Hearing Aid Benefit (APHAB)
Time Frame: Change from baseline assessment to final assessment after 30 day field trial use.
The Abbreviated Profile of Hearing Aid Benefit (APHAB) is a 24 item self-assessment inventory in which patients report the amount of trouble they experience hearing and communicating in noise in different everyday listening environments. Benefit is calculated by comparing the patient's reported difficulty in the unaided condition with their amount of difficulty when using amplification. The APHAB produces scores for 4 subscales: Ease of Communication (EC), Reverberation (RV), Background Noise (BN), and Aversiveness (AV).The final score is determined by subtracting the aided average from the unaided average, keeping in mind that the score indicates how frequently the individual experiences communication difficulty. Therefore a higher score indicates a poorer outcome. (Minimum score 1% to a maximum score of 99%).
Secondary Outcomes
- International Outcome Inventory for Hearing Aids (IOI-HA)(Final assessment after 30 day field use)
- QuickSIN Speech in Noise Test(Baseline and benefit at the end of 30 day field use)
- Digits-in-noise Test (DIN)(Baseline unaided test and aided fitting final assessment after 30 day field use)
- Live Speech Mapping Using Real Ear Measurements (REM)(Final assessment after 30 day field use)